Industry: Biomedical Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A start-up company established in Strasbourg, France, aims to develop candidate drugs to treat cancer patients.
The company has a reserve of original therapeutic molecular technology aimed at the survival mechanism of cancer cells. Its candidate targeted drugs are aimed at BiP (protein, the key to the survival of cancer cells), which can inhibit BiP and make cancer cells "burn" by inducing pressure, which is its original technology: BiP-ER therapy.
The company's candidate drug BPR001 is about to enter the clinical stage to treat patients with gastrointestinal cancer who have no or little response to the existing course of treatment (there are more than 500,000 patients with gastric cancer alone every year in the world). Its second candidate drug is in the 24-month clinical stage, aiming at treating melanoma patients. The company completed the seed round financing in November 2022 to start the preclinical study of BPR001.
Cooperation mode:
The company is seeking a round of financing to verify the efficacy of its candidate drugs in patients.